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Abstract
Background: Bleeding is a recognized complication of native percutaneous renal biopsy. This study aimed to describe the in-
cidence of major bleeding after biopsy in a single centre over a 15-year period and examine factors associated with major
bleeding.
Methods: We identified consecutive adult patients undergoing ultrasound-guided native renal biopsy in the Glasgow Renal
and Transplant Unit from 2000 to 2014. From the electronic patient record, we collected data pertaining to biopsy indication,
pre- and post-biopsy laboratory measurements, prescribed medication and diagnosis. Aspirin was routinely continued. We
defined major bleeding post-biopsy as the need for blood transfusion, surgical or radiological intervention or death. Binary
logistic regression analysis was used to assess factors associated with increased risk of major bleeding.
Results: There were 2563 patients who underwent native renal biopsy (1499 elective, 1064 emergency). The average age of
patients was 57 (SD 17) years and 57.4% were male. Overall, the rate of major bleeding was 2.2%. In all, 46 patients required
transfusion (1.8%), 9 patients underwent embolization (0.4%), no patient required nephrectomy and 1 patient died as a result
of a significant late retroperitoneal bleed. Major bleeding was more common in those undergoing emergency compared
with elective renal biopsy (3.4 versus 1.1%; P<0.001). Aspirin was being taken at the time of biopsy in 327 of 1509 patients,
with no significant increase in the risk of major bleeding (P¼0.93). Body mass index (BMI) data were available for 546 pa-
tients, with no increased risk of major bleeding in 207 patients classified as obese (BMI >30).
Conclusions: The risk of major bleeding following native renal biopsy in the modern era is low. Complications are more
common when biopsy is conducted as an emergency, which has implications for obtaining informed consent. Our data sup-
port the strategy of not stopping aspirin before renal biopsy.
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Introduction
Native renal biopsy is the definitive diagnostic test for renal par-
enchymal disease and is generally considered a safe procedure.
The reported complication rates are low [1–3], particularly since
the move away from manual biopsy needles in favour of spring-
loaded biopsy guns [4]. However, published data relating to the
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risk of native renal biopsy are often derived from small single
centres or utilize historic cohorts covering several decades, dur-
ing which the case mix and biopsy method have changed.
Available data are lacking relating to risks in the modern era.
Bleeding remains the greatest risk after percutaneous renal
biopsy and can be severe or even life-threatening. Efforts are
made in most modern renal units to minimize the risk of bleed-
ing by checking markers of blood coagulation, avoiding renal bi-
opsy in uncontrolled hypertension and being vigilant of the
prevalent prescription of antiplatelet and anticoagulant
medications.
There is no consensus on whether it is safe to perform renal
biopsy while a patient is taking aspirin. There are limited data
available, and concern about a major iatrogenic bleed means
that most units routinely withhold aspirin for up to 7 days in
advance of elective renal biopsy. Many patients with chronic
kidney disease have significant documented cardiovascular
morbidity. A meta-analysis of 50 279 patients at risk for coron-
ary artery disease demonstrated a 3-fold increase in major ad-
verse cardiac events after discontinuation of aspirin [5]. The
median time to infarction was 10.0 6 1.9 days. Routine suspen-
sion of aspirin for a week or more around the time of biopsy is
not a benign intervention. Some centres take this concern fur-
ther and administer procoagulants to patients with prolonged
bleeding times or those perceived to be at greatest risk, again a
practice without evidence.
Furthermore, other factors associated with an increased risk
of bleeding may include being older, having a higher serum cre-
atinine, higher systolic blood pressure or use of a larger needle
gauge [4]. We observed that we were undertaking renal biopsy
in a greater proportion of patients who were obese and we had
concerns over whether these patients were at increased risk.
The Glasgow Renal and Transplant Unit provides tertiary
nephrology services for a population of 1.6 million people.
Routine practice in our centre has been for renal biopsy to be
performed on the ward by the attending nephrologist. As such,
we have multiple operators but a single method of biopsy led by
protocol. We previously studied the impact of discontinuing as-
pirin prior to native biopsy and found no reduction in events [6]
and therefore our practice is to continue aspirin.
Given the degree of uncertainty in the literature and lack of
uniform practice, we extended our previous cohort of patients
and aimed to study factors associated with an increased risk of
significant bleeding in patients undergoing native renal biopsy.
Materials and methods
Adult patients undergoing native renal biopsy in the Glasgow
Renal and Transplant Unit from 2000 to 2014 were identified.
Biopsies were performed using real-time ultrasound (US) guid-
ance (Titan, Sonosite, Herts, UK) and disposable 16-gauge
spring-loaded biopsy guns (Bard Max Core, CR Bard, Covington,
GA, USA) as described from our previous cohort [6]. Usual prac-
tice was to obtain between one and three cores of renal cortex;
on no occasion were more than five passes attempted to obtain
tissue. To minimize bleeding risk, we used the following pre-
biopsy parameters as a guide: prothrombin time (PT) < 15 s,
platelet count  100  109/L and blood pressure controlled
where possible, though our protocol does not call for a specific
blood pressure target. Aspirin was routinely continued but clo-
pidogrel and warfarin were stopped for 7 days or until PT was
<15 s, respectively. Bleeding times were not checked and proco-
agulants were not administered. If there was any uncertainty in
the decision to proceed, consultant opinion was sought.
Patients undergoing native renal biopsy were expected to have
a formal departmental US scan within 6 months before biopsy.
Renal biopsy was not performed if there was evidence of active,
untreated urinary infection.
Patients who underwent a day case procedure were rou-
tinely observed for 6 h and were discharged home if there was
no evidence of bleeding and they did not live alone. In circum-
stances where the biopsy was deemed high risk, including frail
patients or those travelling long distances from home, patients
were kept overnight for monitoring. We performed repeat
haemoglobin if bleeding was suspected or if patients had an
overnight stay. We did not perform US scanning after a biopsy
unless bleeding was suspected clinically.
Data were extracted from the prospectively completed elec-
tronic patient record for biopsy indication, pre-biopsy haemo-
globin, platelet count, PT, estimated glomerular filtration rate
(eGFR), serum creatinine, urinary protein:creatinine ratio, body
mass index (BMI), use of antiplatelets or anticoagulants and
diagnosis. BMI was calculated, with BMI <25 kg/m2 being classi-
fied as healthy weight, 25–29.9 kg/m2 as overweight and  30 kg/
m2 as obese. We defined major bleeding post-biopsy as the
need for blood transfusion, surgical or radiological intervention
or death. We have reported rates of minor bleeding as a haemo-
globin drop >2 g/L or other morbidity, which includes visible
haematuria, requirement for catheter/irrigation, haematoma
not requiring transfusion, additional period of observation or
loin pain. Patients who underwent renal biopsy during a non-
elective admission to the renal unit for investigation and treat-
ment of renal disease (usually acute kidney injury or nephrotic
syndrome) were considered to have undergone biopsy as an
emergency. Binary logistic regression analysis was used to as-
sess factors associated with an increased risk of major bleeding
(SPSS version 22, IBM, Armonk, NY, USA). Comparisons between
groups used t-test, one-way analysis of variance, Mann–
Whitney U test or chi-square test as appropriate.
Results
Baseline demographics
There were 2619 patients who underwent native renal biopsy
during the 15-year period. We excluded 56 procedures con-
ducted in the radiology department (by a consultant radiolo-
gist), which were US- or computed tomography–guided (no
transjugular biopsies), leaving 2563 biopsies (1499 elective, 1064
emergency). There was a slight preponderance of male patients
(57.4%) and the mean age was 57 (SD 17) years. In all, 497 (19.4%)
were undertaken as day cases. Baseline demographics are
shown in Table 1. There were >55 operators over the 15 years
studied, of whom >90% were nephrology trainees.
The rate of major bleeding overall was 2.2%: transfusion
1.8%, embolization 0.4% and death 0.1%. During the study, one
patient died as a direct result of renal biopsy. This patient had a
history of recurrent pulmonary emboli and restarted warfarin
7 days after biopsy. He presented on day 12 after biopsy with se-
vere abdominal pain, vomiting and shock. Post-mortem exam-
ination confirmed a late retroperitoneal haemorrhage directly
related to the renal biopsy.
The rate of major bleeding in 56 radiologist-performed biop-
sies excluded from the main analysis was not statistically differ-
ent from that in nephrologist-performed biopsies (3.8% versus
2.1%; P ¼ 0.239). Of the two patients who suffered major bleeding
after biopsy performed by a radiologist, one patient underwent
renal arterial embolization and one received a blood transfusion.
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There were no deaths. There was no significant difference in age
or eGFR between patients who had native biopsy performed by a
nephrologist on the nephrology ward versus by a radiologist in
the radiology department, but those performed by a radiologist
had a significantly higher mean BMI (28 versus 32; P ¼ 0.02).
Elective versus emergency biopsy
Biopsies were more likely to be performed electively (58.5%).
Those who had a biopsy conducted as an emergency were sig-
nificantly older, had worse renal function and more proteinuria
(Table 1). Major bleeding was more common in those undergo-
ing emergency compared with elective renal biopsy (1.1 versus
3.4%; P < 0.001) (Table 2).
Primary renal diagnosis
Major bleeding was more common in 336 patients with renal vas-
culitis (5.1 versus 2.1%), with the majority requiring blood
transfusion (Table 3). No differences were observed in the rate of
complications for patients in whom other diagnoses were made.
Biopsy adequacy
Tissue was adequate for diagnosis in 93.6% of cases. In the 163
cases in which biopsy was non-diagnostic, there was no signifi-
cant difference in the rate of major complications (3.0 versus
2.2%; P ¼ 0.43).
Medicines
Complete medication data relating to antiplatelet or anticoagu-
lant use were available for 1509 patients. There were 327 pa-
tients who were taking aspirin (75 mg) at the time of biopsy and
there was no increased risk of major bleeding (Table 4). In pa-
tients taking aspirin, there was no significant increased risk of a
haemoglobin decrease >2 g/L (2.4 versus 2.2%; P ¼ 0.79) or other
morbidity (1.5 versus 3.0%; P ¼ 0.15). In all, 29 patients stopped
Table 1. Baseline demographic data for 2563 included patients undergoing percutaneous renal biopsy
Baseline data All patients (n ¼ 2563) Elective (n ¼ 1499, 58.5%) Emergency (n ¼ 1064, 42.5%) P-value (chi-square)
Male (%) 57.4 57.9 56.3 0.216
Mean age (years) 56.9 (17.2) 54.1 (16.8) 60.8 (17.0) <0.001
Pre-Hb (g/L) 11.6 (2.4) 12.4 (2.2) 10.4 (2.1) <0.001
Post-Hb (g/L) 11.0 (2.4) 11.9 (2.3) 10.0 (2.0) <0.001
Hb change (g/L) 0.2 (0.9) 0.4 (0.8) 0.3 (0.9) 0.001
eGFR (mL/min/1.73 m2) 33.9 (30.4) 48.1 (30.7) 24.4 (24.8) <0.001
Urine PCR (mg/mmol) 288 (116–641) 251 (109–565) 357 (130–801) <0.001
Urine ACR (mg/mmol) 175 (52–443) 176 (56–411) 172 (43–181) 0.500
Platelets (109/L) 266 (211–331) 270 (85) 303 (136) <0.001
Prothrombin time (s) 11.3 (2.0) 11.0 (2.2) 11.8 (1.6) <0.001
Systolic BP (mmHg) 139 (20) 139 (20) 139 (19) 0.836
Diastolic BP (mmHg) 77 (11) 78 (12) 76 (11) 0.717
Hb, haemoglobin; PCR, protein:creatinine ratio; ACR, albumin:creatinine ratio; BP, blood pressure.
Table 2. Major bleeding rate after percutaneous renal biopsy
Major bleeding type All biopsies (n ¼ 2563) Elective (n ¼ 1499) Emergency (n ¼ 1064) P-value (chi-square)
Overall major bleeding 56 (2.2%) 17 (1.1%) 36 (3.4%) <0.001
Transfusion 46 (1.8%) 14 (0.9%) 32 (3.0%) <0.001
Embolization 9 (0.4%) 2 (0.1%) 7 (0.7%) 0.03
Death 1 (0.04%) 1 (0.04%) 0 (0.0%)
Other morbidity 59 (2.3%) 48 (3.2%) 11 (1.0%) <0.001
Haemoglobin decrease>2 g/L 74 (2.9%) 39 (2.6%) 35 (3.3%) 0.31
Complications were more common in emergency versus elective procedures.
Table 3. Major bleeding rate by diagnosis after percutaneous native renal biopsy
Diagnosis on biopsy n Major bleeding Transfusion Embolization
Glomerulonephritis including HSP 1143 13 (1.1%) 12 (1.0%) 2 (0.2%)
Vasculitis 336 17 (5.1%) 14 (4.2%) 2 (0.6%)
Interstitial disease including CPN 199 4 (2.0%) 4 (2.0%) 0 (0.0%)
Chronic ischaemia 145 2 (1.4%) 0 (0.0%) 1 (0.7%)
Diabetic nephropathy 139 4 (2.9%) 4 (2.9%) 0 (0.0%)
Amyloid/myeloma 140 1 (0.7%) 1 (0.7%) 0 (0.0%)
Lupus nephritis 111 2 (1.8%) 2 (2.6%) 1 (0.9%)
Acute tubular injury 96 0 (0.0%) 0 (0.0%) 0 (0.0%)
Others 88 5 (5.7%) 4 (4.5%) 3 (3.4%)
Non-diagnostic 164 5 (3.0%) 5 (3.0%) 0 (0.0%)
CPN, Chlamydia pneumoniae; HSP, Henoch–Scho¨nlein Purpura.
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clopidogrel (>5 days before) and 13 continued it during biopsy.
In these cases, clopidogrel was continued due to a perceived in-
creased risk of stopping, including recent acute coronary syn-
drome or previous coronary stenting. Warfarin was stopped
temporarily in advance of biopsy in all 61 relevant cases. There
was no increased bleeding risk associated with the use of clopi-
dogrel or warfarin, although numbers are small (data not
shown).
Obesity
Height and weight were available for 1045 patients. The mean
BMI was 28.1 (SD 6.0) kg/m2 (range 12.9 – 55.4). A total of 326
were healthy weight, 373 were overweight and 346 were obese.
There were 46 patients who had a biopsy with a recorded BMI
> 40. Rates of complications were 3.4, 1.1 and 0.9%, respectively
(P ¼ 0.06), for healthy weight, overweight and obese, suggesting
that renal biopsy in obese patients is associated with lower
bleeding risk than in patients with a normal BMI.
Analysis of other demographic factors associated with
increased risk of bleeding
In binary logistic regression analyses, pre-biopsy platelet count,
PT, blood pressure and proteinuria were not associated with a
risk of bleeding. Increased age and decreased eGFR were associ-
ated with an increased risk of major bleeding (Table 5).
Comparison with previous cohort
The demographics of this larger cohort, including age, sex, eGFR
at biopsy and urgency of biopsy are similar to those of our previ-
ously published cohort [6].
Discussion
In this study we demonstrated that native renal biopsy is a safe
procedure. Older patients, those with worse renal function and
those with vasculitis undergoing the procedure as an
emergency are at greatest risk. Continuing aspirin is not associ-
ated with a risk of major bleeding and a BMI >30 kg/m2 is not a
risk factor for bleeding.
Our reported complication rates are in keeping with other
available large-scale studies of native renal biopsy [1, 2, 7–9].
Our complication rates are similar to those described in the
largest available meta-analysis, assessing 34 published studies
of 9474 biopsies from 1980 to 2011 [3], which included a subset
of the patients presented in the present analysis published in
2008 [6]. All included studies used real-time US guidance and
biopsies were taken using automated spring-loaded devices,
which would be in keeping with modern techniques. Other
large, single-centre case series have reported much greater
complication rates (transfusion rates 5–9%) [10–13]. It has been
suggested that this may be because these large academic
centres have a greater proportion of biopsy procedures per-
formed by nephrology trainees and may have a greater propor-
tion of high-risk patients [4]. The Glasgow Renal and Transplant
Unit is the second largest renal centre in the UK, serving a popu-
lation of 1.6 million. More than 90% of our biopsies are per-
formed by nephrology trainees and we have included all
biopsies conducted in this time period regardless of risk stratifi-
cation. We believe our data are representative of native renal bi-
opsy complications in a large academic renal unit.
In a large case series of 15 181 percutaneous core biopsies,
there was no increased risk of bleeding in 5832 renal biopsies (na-
tive and transplant) in patients taking aspirin (n ¼ 1270) versus no
aspirin use (1.0 versus 0.6%; P ¼ 0.53) [14]. A recent review of best
practice in native renal biopsy has been published and discusses
the issue of using aspirin around the time of biopsy, concluding
that there are insufficient data to safely answer this question [4].
Our practice is to continue aspirin and to discontinue other anti-
platelets and anticoagulants. As a direct comparison with our own
practice, our major bleeding rate has not increased since we
changed our practice to routinely continue aspirin [6].
In this study we have focused on what we believe to be the
major bleeding of native renal biopsy, in line with previously
published reports. Although we have reported rates of haemo-
globin decrease and other morbidity, this study was not de-
signed to analyse these complications and it is likely that the
rates of minor bleeding complications are underreported.
The increased rate of blood transfusion observed in patients
with vasculitis may be confounded by the high transfusion re-
quirements seen acutely in these patients when they present.
Whether the vasculitic process in the kidney influences the risk
of bleeding is unclear. Other primary renal diagnoses, such as
amyloid, have also been associated with an increased risk of
bleeding [15], although we found no evidence of such an associ-
ation in this study.
Obesity is a worldwide problem and is associated with the
development of renal diseases. As such, renal biopsy will be
Table 4. Bleeding rate according to aspirin use at the time of biopsy
Aspirin status
Total [n ¼ 2536 (no aspirin,
n ¼ 1182; aspirin, n ¼ 327)]
Elective [total, n ¼ 1499 (no
aspirin, n ¼ 692; aspirin, n ¼ 207)]
Emergency [total, n ¼ 1064
(no aspirin, n ¼ 490; aspirin, n ¼ 120)]
Death Tfusion Embn Major bleed Death Tfusion Embn Major bleed Death Tfusion Embn Major bleed
No aspirin 1 (0.1%) 22 (1.9%) 7 (0.6%) 30 (2.5%) 1 (0.1%) 11 (1.6%) 2 (0.3%) 14 (2.0%) 0 (0.0%) 11 (2.2%) 5 (1.0%) 16 (3.3%)
Aspirin 0 (0.0%) 5 (1.5%) 0 (0.0%) 5 (1.6%) 0 (0.0%) 2 (1.0%) 0 (0.0%) 2 (1.0%) 0 (0.0%) 3 (2.5%) 0 (0.0%) 3 (2.5%)
Unknown 0 (0.0%) 19 (1.8%) 2 (0.2%) 21 (2.0%) 0 (0.0%) 1 (0.2%) 0 (0.0%) 1 (0.2%) 0 (0.0%) 18 (4.0%) 2 (0.4%) 20 (4.4%)
P-value (chi-square) 0.56 0.92 0.14 0.47 0.56 0.03 0.31 0.01 0.29 0.35 0.50
Tfusion, transfusion; Embn, embolization.
Table 5. Binary logistic regression analysis of factors associated with
increased risk of major bleeding
Risk factor Odds ratio 95% confidence interval P-value
Increasing age 1.025 1.007–1.043 0.006
Decreasing eGFR 1.034 1.018–1.050 <0.001
Systolic BP 1.018 0.996–1.040 0.113
BMI > 30 0.363 0.105–1.254 0.154
BP, blood pressure.
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required more frequently in patients with high BMIs. In this
study we biopsied a large number of patients who were clinic-
ally obese but observed no increased risk of complications in
these patients, which is reassuring.
We acknowledge constraints in the interpretation of these
data. In this retrospective observational study, we did not ob-
serve an increased risk of complications in patients taking anti-
platelet agents, but the absolute number of complications in
this group was small. The nature and size of this study is not
powered to give a definitive answer to the question of the safety
of using aspirin at the time of biopsy: prospective confirmation
would be required. Nevertheless, we believe we have described
data that compare favourably with other published studies
from a large cohort of patients who have undergone native
renal biopsy in a ‘real-world’ setting.
In summary, the risk of major bleeding following native
renal biopsy in the modern era is low. Complications are more
common when biopsy is conducted as an emergency, which
has implications for obtaining informed consent. Obesity does
not appear to be a risk factor for major bleeding. In the absence
of large-scale, randomized clinical trials, our data support the
routine continuation of aspirin at the time of renal biopsy, par-
ticularly given that discontinuing it may increase the risk of
thrombotic events in those at high risk of cardiovascular
disease.
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